Standout Papers

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell ma... 2010 2026 2015 2020 583
  1. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability (2010)
    Brian J. Lannutti, Sarah Meadows et al. Blood

Immediate Impact

5 by Nobel laureates 23 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Naturally occurring T cell mutations enhance engineered T cell therapies
2024 StandoutNature
Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity
2021 StandoutScience
2 intermediate papers

Works of Sarah Meadows being referenced

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
2011
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Sarah Meadows 929 856 617 23 1.7k
Janet Glassford 188 971 148 22 1.5k
Dana E. Cullen 459 1472 85 15 2.2k
Stefania Gobessi 944 693 494 33 1.5k
Cornelia Rudolph 213 1383 110 40 2.0k
Robert Mashal 200 654 169 24 1.4k
Emma Peskett 402 990 117 14 1.7k
Demetrios Kalaitzidis 238 1395 117 27 2.1k
Yuko Tadokoro 309 1208 71 36 2.2k
Sabine Quief 398 942 522 29 1.8k
Valerie L. Goss 257 1650 76 15 2.2k

All Works

Loading papers...

Rankless by CCL
2026